155 related articles for article (PubMed ID: 8489107)
1. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group.
Wolff SN; Fay JW; Herzig RH; Greer JP; Dummer S; Brown RA; Collins RH; Stevens DA; Herzig GP
Ann Intern Med; 1993 Jun; 118(12):937-42. PubMed ID: 8489107
[TBL] [Abstract][Full Text] [Related]
2. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
[TBL] [Abstract][Full Text] [Related]
3. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts.
Feinstein LC; Seidel K; Jocum J; Bowden RA; Anasetti C; Deeg HJ; Flowers ME; Kansu E; Martin PJ; Nash RA; Storek J; Etzioni R; Applebaum FR; Hansen JA; Storb R; Sullivan KM
Biol Blood Marrow Transplant; 1999; 5(6):369-78. PubMed ID: 10595814
[TBL] [Abstract][Full Text] [Related]
4. Intravenous lipid dose and incidence of bacteremia and fungemia in patients undergoing bone marrow transplantation.
Lenssen P; Bruemmer BA; Bowden RA; Gooley T; Aker SN; Mattson D
Am J Clin Nutr; 1998 May; 67(5):927-33. PubMed ID: 9583851
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.
Sullivan KM; Storek J; Kopecky KJ; Jocom J; Longton G; Flowers M; Siadak M; Nims J; Witherspoon RP; Anasetti C; Appelbaum FR; Bowden RA; Buckner CD; Crawford SW; Deeg HJ; Hansen JA; McDonald GB; Sanders JE; Storb R
Biol Blood Marrow Transplant; 1996 Feb; 2(1):44-53. PubMed ID: 9078354
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
7. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease.
Sullivan KM
Clin Exp Immunol; 1996 May; 104 Suppl 1():43-8. PubMed ID: 8625543
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
Winston DJ; Ho WG; Bartoni K; Champlin RE
Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.
Sullivan KM; Kopecky KJ; Jocom J; Fisher L; Buckner CD; Meyers JD; Counts GW; Bowden RA; Peterson FB; Witherspoon RP
N Engl J Med; 1990 Sep; 323(11):705-12. PubMed ID: 2167452
[TBL] [Abstract][Full Text] [Related]
11. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Weight-Based Dosing Strategies for Intravenous Immunoglobulin in Patients with Hematologic Malignancies.
Stump SE; Schepers AJ; Jones AR; Alexander MD; Auten JJ
Pharmacotherapy; 2017 Dec; 37(12):1530-1536. PubMed ID: 29028117
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants.
Abdel-Mageed A; Graham-Pole J; Del Rosario ML; Longmate J; Ochoa S; Amylon M; Elfenbein GJ; Janiec J; Jansen J; Lazarus HM
Bone Marrow Transplant; 1999 May; 23(9):929-32. PubMed ID: 10338049
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Mofenson LM; Moye J; Bethel J; Hirschhorn R; Jordan C; Nugent R
JAMA; 1992 Jul 22-29; 268(4):483-8. PubMed ID: 1352363
[TBL] [Abstract][Full Text] [Related]
16. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
[TBL] [Abstract][Full Text] [Related]
17. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy.
Schwaighofer H; Oberhuber G; Hebart H; Einsele H; Herold M; Nachbaur D; Eibl B; Tilg H; Kropshofer G; Ferrara JL; Niederwieser D
Transplantation; 1997 Jan; 63(1):52-6. PubMed ID: 9000660
[TBL] [Abstract][Full Text] [Related]
18. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF.
Offidani M; Corvatta L; Olivieri A; Rupoli S; Frayfer J; Mele A; Manso E; Montanari M; Centurioni R; Leoni P
Bone Marrow Transplant; 1999 Nov; 24(10):1079-87. PubMed ID: 10578158
[TBL] [Abstract][Full Text] [Related]
19. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.
Essell JH; Schroeder MT; Harman GS; Halvorson R; Lew V; Callander N; Snyder M; Lewis SK; Allerton JP; Thompson JM
Ann Intern Med; 1998 Jun; 128(12 Pt 1):975-81. PubMed ID: 9625683
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications.
Blombery P; Prince HM; Worth LJ; Main J; Yang M; Wood EM; Westerman DA
Ann Hematol; 2011 Oct; 90(10):1167-72. PubMed ID: 21674144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
